Introduction
Antibiotic resistance is a growing global health threat of broad concern where increased antibiotic consumption is driving resistance [1] . Consequently, antibiotics are becoming less effective or even ineffective, resulting in an accelerating health security emergency that is rapidly outpacing available treatment options [2] . Surveillance of antimicrobial resistance tracks changes in microorganisms and allows the early detection of resistant strains of public health importance, while surveillance of antibiotic consumption allows the quantification of the selection pressure on microbial populations and serves as an outcome measure of antibiotic stewardship programs. According to the World Health Organization (WHO), linking the surveillance findings to patterns of antibiotic consumption has proven to be a crucial factor driving political commitment to successful resistance containment campaigns. In this context, hospitals represent 'hot spots' for selective pressure on micro-organisms [3] where the lack of control of antimicrobial use will inevitably lead to overuse, poor outcomes and higher healthcare costs [4] . Numerous initiatives in recent years have encouraged hospitals to conduct surveillance of antimicrobial consumption in order to identify possible overuse and misuse [5] . In fact, in high income countries, networks such as European Surveillance on Antibiotics Consumption Network database (maintained by European Centre for Disease Control for European Union (EU) countries) [6] and resistance map in the United States of America have enabled greater understanding of antibiotic use; however, there are still gaps in data worldwide, especially in resource limited settings [7] Few published descriptions [5, 8] or comparisons of antibiotic consumption are available [9, 10, 34, 35] particularly in the Mediterranean region, identified as an area of hyper-endemicity for multiresistant hospital pathogens [11] . In Lebanon, there is a lack of information concerning the level of antibiotic consumption in the hospitals. The objective of the study is to address this issue and focus on the intensity of antibiotic use in participating hospitals and benchmark with published data expressed in daily divided dose per 100-bed-days (DDD/100BD) in neighboring Mediterranean in particular and other available data worldwide in general. Our aim is to give an insight of antibiotic prescribing patterns and provide a baseline data for future benchmark and correlation with changes in antibiotic susceptibility testing and trends of antimicrobial resistance in the hospital settings.
Material and methods

Study design
This is an observational cross-sectional study conducted for a period of 12-month in 2012 using data from pharmacy records aggregated at hospital level.
Data collection
Following the approval of the Institutional Review Board, fifty two hospitals were asked to fill out an anonymous questionnaire. Administrative data consisted of the hospital number of beds and the occupancy rate for a period of 12 month during the year 2012 allowing the determination of the number of Bed-days, a standardized figure that provides a degree of comparison among different institutions. Other requested data included, the hospital status, number of intensive care unit (ICU) beds and the availability of a transplantation and/or oncology unit, considered primary areas of focus due to high rates of antibiotic usage [12] [13] [14] [15] [16] . Data concerning the consumption of antibiotics for systemic use were collected from the hospital pharmacy computer records representing the total number of antibiotics per unit dose per category, actually prescribed and consumed during the study period [31] . The validity of the data was not tested since all collected data were retrieved from computerized reports however we highlight the presence of bias due to peculiarities of prescribing systems and the possibility of including an element of ambulatory care mix in the consumption record. Using ABC Calc. software version 3.1, antibiotic consumption data were aggregated at the fifth level of the ATC classification and expressed in Defined Daily Doses (DDD).
Hospital demographic data
Twenty seven general private and public hospitals participated in the survey from different regions in Lebanon. Patient's age ranged from 18 to 85 years old. All participating hospitals have both medical and surgical units, but the number of beds including ICU beds, the occupancy rate as well as the availability of an oncology and/or a transplantation unit varied.
Antibiotic consumption
Antibiotic consumption data retrieved from pharmacy records, were collated on a standardized file derived from the ABC Calc software version 3.1 [developed by the Danish Statens Serum Institute (http://www.escmid.org/)] on a Microsoft Excel application (Microsoft Corporation, Redmond, WA, USA) together with administrative data. The Excel application included all antibacterial drugs marketed in Lebanon for systemic use J01 ATC group [17, 18] . As recommended by the WHO, ABC Calc reports hospital antibiotic consumption as a number of DDD/100BD. For a specific drug, the DDD corresponds to the assumed average daily dose for its main indication in adults. ABC Calc uses the 2006 version of the ''ATC (Anatomical Therapeutic Chemical) Index with DDDs''. Antibiotics were recorded by their non-proprietary names. Each drug was then given its chemical name and a code according to the ATC classification that comprises 5 levels. The first level is the anatomical group (e.g. anti-infective for systemic use), the second is the therapeutic group (antibiotics for systemic use), the third is a therapeutic subgroup, the fourth gives the chemical form and the fifth is a chemical subgroup. For the purpose of our study, all five levels were used [19] .
Hospital antibiotic consumption was divided into eight main antibiotic groups: penicillins (J01C); cephalosporins, carbapenems and monobactams (J01D); tetracyclines (J01A); macrolides + lincosamides + streptogramins (J01F); quinolones (J01M); sulphonamides (J01E); aminoglycosides (J01G); and 'others' [20] , including (J01XA) glycopeptides, (J01XD) imidazoles, (J01XX) linezolid and (J01XB) polymyxin. Broad spectrum antibiotics included antipseudomonal penicillins (J01CA) fourth generation cephalosporins (J01DE), carbapenems (J01DH), glycopeptides (J01XD) and quinolones (J01M).
Statistical analysis
Data was entered and analyzed using SPSS version 17.0. In the descriptive analysis, frequency and percentages were presented for nominal variables, while means and standard deviations were used for continuous variables. For bivariate analysis, ANOVA was used to compare means between three groups or more, while Student test was used to compare between two groups, provided distribution was normal and variances were homogeneous; if not, non-parametric tests were used: Kruskall-Wallis and Mann-Whitney tests, respectively. In all cases, a p-value <0.050 was considered statistically significant.
Results
Hospital characteristics
According to the order of Hospitals, there are one hundred thirty eight hospitals in Lebanon where nine are classified as teaching hospitals. Among one hundred nineteen non-teaching hospitals, nineteen are considered long-term care settings and the remaining one hundred ten are short -stay acute care hospitals. Two types of hospitals were excluded from the study: teaching hospitals because of extensively long and complicated Institutional Board Review procedures and long-term stay hospitals. Among 52 randomly contacted hospitals from different regions in Lebanon including Beirut, Mount Lebanon, Bekaa, North and South Lebanon, only 27 general hospitals participated in the survey among which 89% were private and 11% public hospitals. All hospitals required to remain anonymous and refused to give any data concerning their annual report of susceptibility profiles of bacterial strains. Hospitals participating in the survey were from different urban regions in Lebanon, 48% from Mount Lebanon, 19% from the Bekaa region, 15% from Beirut, 11% from the South and 7% from the North. Among them, 37% of hospitals have less than 80 beds and 63% have more than 7 ICU beds while 70% have an oncology unit and 96% do not have a transplantation unit. The occupancy rate was less than 53% in 33% of the hospitals and ranged between 54% and 70% in 37% of hospitals while it was 70% in more than 30% of hospitals (Table 1) .
Hospital characteristics associated with antibiotic consumption
The average antibiotic consumption in the hospitals is 72.56 DDD/100 BD with a total broad spectrum antibiotic consumption of 12.14 DDD/100 BD. The most commonly used antibiotics were Amoxycillin/Clavulanic acid, Ceftriaxone, Amoxycillin and Cefuroxime for parenteral use with Amoxycillin/Clavulanic acid consisting of 59% of total use ( Table 2) . The average antibiotic consumption in public hospitals is 66 DDD/100 BD whereas it is 73 DDD/100 BD in private hospitals with a p value of 0.51. No significant difference was found for any antibiotic consumption between public and private hospitals (p > 0.05 for all).
The consumption of beta-lactams, cephalosporins, carbapenems,monobactams and quinolones did not vary significantly by region, occupancy rate, number of beds including the number of ICU bed or the availability of an oncology or a transplantation unit.
The consumption of antipseudomonalpenicillinsvaried by region with the highest value noted in Beirut (p = 0.044). In addition, the use of aminoglycosides (p = 0.034), carbapenems (p = 0.042) and glycopeptides (p = 0.019)increased significantly when the occupancy rate decreased in the hospitals (Table 3 ).
Discussion
In Lebanese non-teaching hospitals, our data showed that antibiotic consumption did not vary significantly by region, occupancy rate, and number of beds including number of ICU bed or the availability of an oncology or a transplantation unit.
Results from our survey demonstrated that average antibiotic consumption in Lebanese nonteaching hospitals excluding pediatric cases was 72.55 DDD/100 BD. This value was lower compared to the findings of the ARMed project [21] that benchmarked antibiotic use prospectively in hospitals from southern and eastern Mediterranean countries and showed that the median total Occupancy rate p = 0.057 p = 0.092 p = 0.034 p = 0.042 p = 0.019 53% or less 83. 20 antibiotic use was 112 DDD/100BD, with an interquartile range of 84-428 DDD/100BD. This may be due to the hospitals type included in the study or to a more rigid implementation of antibiotic restriction programs as stressed by the hospital accreditation process undertaken by the Ministry of Health in Lebanon in 2011. Nevertheless, our finding is comparable to the USA 2002-2003 study (79 DDD/100BD) [22] , while in Europe antibiotic use was lower as reported in France by Dumartin et al., 37-39 DDD/100BD [23] and 43.5 RDD/100 patient days (median) with an interquartile range of 36-48 RDD/100 -corresponding to a median of 64.4 DDD/100 (interquartile range, 53-73 DDD/100) in a published study in Germany in 2015 [29] . In Sweden a range of 56-59 DDD/100BD in [24] and 58-91 DDD/100BD in Denmark [25] and finally 50-70 DDD/100BD in the Netherlands [26] .
In addition, our data findings showed that regional differences only affected the consumption of Penicillins with antipseudomonal activity and that the decrease in the occupancy rate was inversely proportional to the consumption of Carbapenems, Glycopeptides and aminoglycosides. Broad spectrum antibiotic use, specifically carbapenems and fourth generation cephalosporins increased significantly with the availability of a transplantation unit, a service only available in <4% of participating hospitals, while only Carbapenems use was significantly higher in case of availability of an oncology unit.
Number of beds, including the number of ICU beds did not significantly affect the consumption of antibiotics including broad spectrum antibiotics which means that antibiotic consumption data should preferably be collected at ward level in order to have more accurate results to benchmark.
Discussion Limitations
Results from our survey demonstrated that average antibiotic consumption in Lebanese nonteaching hospitals excluding pediatric cases was 72.55 DDD/100 BD. This value was lower compared to the findings of the ARMed project [21] that benchmarked antibiotic use prospectively in hospitals from southern and eastern Mediterranean countries and showed that the median total antibiotic use was 112 DDD/100BD, with an inter-quartile range of 84-428 DDD/100BD. This may be due to the hospitals type included in the study or to a more rigid implementation of antibiotic restriction programs as stressed by the hospital accreditation process undertaken by the Ministry of Health in Lebanon in 2011. Nevertheless, our finding is comparable to the USA 2002-2003 study (79 DDD/100BD) [22] , while in Europe antibiotic use was lower as reported in France by Dumartin et al., 37-39 DDD/100BD [23] and 43.5 RDD/100 patient days (median) with an interquartile range of 36-48 RDD/100 -corresponding to a median of 64.4 DDD/100 (interquartile range, 53-73 DDD/100) in a published study in Germany in 2015 [29] . In Sweden a range of 56-59 DDD/100BD in [24] and 58-91 DDD/100BD in Denmark [25] and finally 50-70 DDD/100BD in the Netherlands [26] .
Current and future developments
Currently, the Lebanese Ministry of Health in collaboration with the WHO is mandating the hospitals to submit their yearly susceptibility testing results and to harmonize antimicrobial breakpoints according to international guidelines. It will be important to correlate reported data with patterns of antibiotic consumption in order to monitor progress toward a more prudent antibiotic use [29, 32] .
Conclusion
Our study provides baseline information on antibiotic consumption and emphasis on the need to generalize the findings to encompass all hospitals teaching and non-teaching through the implementation of a national database for the periodic surveillance and benchmark of antibiotic consumption and its correlation with changes in patterns of antibiotic susceptibility testing. Continuous monitoring of antibiotic use will eventually results in optimizing antibiotic prescription and the implementation of national strategies to fight antibiotic resistance and improve patient safety.
